Healthcare utilization among persons living with hiv with attention to the influences of hepatitis

References

2. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PloS one. 2013;8(12):e81355.

3. National Alliance of State and Territorial AIDS Directors. National ADAP Monitoring Project Annual Report. Washington, DC February 2014.

4. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. Aids. Nov 13 2010;24(17):2705-2715.

5. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Medical care. Nov 2006;44(11):990-997.

6. Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Archives of pediatrics & adolescent medicine. Dec 2007;161(12):1162-1168.

7. Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and mortality weekly report. Oct 12 2012;61(40):816-819.

8. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jan 2014;58(1):1-10.

9. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine. Jan 26 2005;23(10):1284-1293.

10. Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression. Psychiatry and clinical neurosciences. Feb 2014;68(2):96-109.

11. Hilsabeck RC, Castellon SA, Hinkin CH. Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jul 1 2005;41 Suppl 1:S38-44.

12. Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. Aids. Oct 2005;19 Suppl 3:S64-71.

13. Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. Journal of acquired immune deficiency syndromes. Apr 1 2005;38(4):432-438.

14. Walkup J, Wei W, Sambamoorthi U, Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. The Psychiatric quarterly. Mar 2008;79(1):43-53.

15. Olatunji BO, Mimiaga MJ, O'Cleirigh C, Safren SA. Review of treatment studies of depression in HIV. Topics in HIV medicine : a publication of the International AIDS Society, USA. Aug-Sep 2006;14(3):112-124.

16. Dalessandro M, Conti CM, Gambi F, et al. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. Journal of clinical psychopharmacology. Feb 2007;27(1):58-61.

17. Winiarski MG, Beckett E, Salcedo J. Outcomes of an inner-city HIV mental health programme integrated with primary care and emphasizing cultural responsiveness. AIDS care. Aug 2005;17(6):747-756.

18. Weaver MR, Conover CJ, Proescholdbell RJ, et al. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. The journal of mental health policy and economics. Mar 2009;12(1):33-46.

19. Alegria M, Chatterji P, Wells K, et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv. Nov 2008;59(11):1264-1272.

20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013; http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 28 October 2013.

21. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/muL and HIV-1 suppression? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 2013;56(9):1340-1343.

22. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Nov 13 2013.

23. Tuma P, Medrano J, Resino S, et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antiviral therapy. 2010;15(6):881-886.

24. Reiberger T, Obermeier M, Payer BA, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antiviral therapy. 2011;16(6):815-824.

25. Vellozzi C, Buchacz K, Baker R, et al. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. Journal of viral hepatitis. May 2011;18(5):316-324.

26. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Jama. Jul 23-30 2014;312(4):353-361.

27. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of internal medicine. Jul 16 2013;159(2):86-96.

28. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. The Lancet. Infectious diseases. Jul 2013;13(7):597-605.

29. Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet. Oct 30 2010;376(9751):1441-1442.

30. Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Apr 2012;54(7):979-983.

31. Fialho R, Keller M, File A, et al. HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder. Journal of the International AIDS Society. 2014;17(4 Suppl 3):19629.

32. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Current opinion in HIV and AIDS. May 2011;6(3):163-168.

33. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for Innate Immune System Activation in HIV Type 1-Infected Elite Controllers. The Journal of infectious diseases. Dec 2 2013.

34. Noel N, Boufassa F, Lecuroux C, et al. Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. AIDS. Feb 20 2014;28(4):467-476.

35. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. The Journal of infectious diseases. Jan 1 2008;197(1):126-133.

36. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. Aids. Nov 28 2012;26(18):2409-2412.

37. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. Aids. Jun 1 2009;23(9):1059-1067.

38. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS pathogens. 2013;9(10):e1003691.

39. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. Jun 1 2009;23(9):1035-1046.

40. Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'. Curr Opin HIV AIDS. Jul 2012;7(4):332-338.

41. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. Jul 31 2010;376(9738):355-366.

42. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. Aids. Sep 27 2002;16(14):1859-1866.

43. Lange CG, Lederman MM, Madero JS, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. Journal of acquired immune deficiency syndromes. May 1 2002;30(1):33-40.

44. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. The Journal of infectious diseases. Oct 15 2011;204(8):1217-1226.

45. Alsina L, Noguera-Julian A, Fortuny C. Impaired cellular immune response to tetanus toxoid but not to cytomegalovirus in effectively HAART-treated HIV-infected children. Vaccine. May 7 2013;31(20):2417-2419.

46. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. Journal of virology. Jan 2009;83(1):329-335.

47. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. The Journal of infectious diseases. Sep 15 2009;200(6):984-990.

48. Hunt PW, Landay AL, Sinclair E, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PloS one. 2011;6(1):e15924.

49. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. The Journal of infectious diseases. Mar 2014;209(6):931-939.